Transcriptome-Derived Ligand-Receptor Interactome of Major PitNET Subgroups

Abstract

Introduction Pituitary neuroendocrine tumors (PitNETs) are rare skull base tumors which can impart significant disability owing to their locally invasive potential. To date, the gamut of PitNET subtypes remains ill-understood at the ligand-receptor (LR) interactome level, potentially limiting therapeutic options. Here, we present findings from in silico analysis of LR complexes formed by PitNETs with clinical presentations of acromegaly, Cushing's disease, high prolactin production, and without symptoms of hormone hypersecretion.

Methods Previously published PitNET gene expression data was acquired from ArrayExpress. These data represented all secretion types. LR interactions were analyzed via a crosstalk score approach.

Results Cortisol (CORT) ligand was significantly involved in tumor-to-tumor signaling across all PitNET subtypes but prolactinomas, which evidenced active CORT depletion. Likewise, CCL25 ligand was implicated in 20% of the top LR complex interactions along the tumor-to-stroma signaling axis, but silent PitNETs reported unique depletion of the CCL25 ligand. Along the stroma-to-tumor signaling axis, all clinical PitNET subtypes enriched stromal vasoactive intestinal polypeptide ligand interactions with tumor secretin receptor. All clinical PitNET subtypes enriched stromal DEFB103B (human β-defensin 103B) ligand interactions with stromal chemokine receptors along the stroma-to-stroma signaling axis. In PitNETs causing Cushing's disease, immune checkpoint ligand CD274 reported high stromal expression, and prolactinomas reported low stromal expression. Moreover, prolactinomas evidenced distinctly high stromal expression of immune-exhausted T cell response marker IL10RA compared with other clinical subtypes.

Conclusion Relative crosstalk score analysis revealed a great diversity of LR complex interactions across clinical PitNET subtypes and between solid tumor compartments. More data are needed to validate these findings and exact clinical importance.

Keywords

PitNET - clinical subtype - Cushing's disease - acromegaly - ligand-receptor interactions - relative crosstalk score

Publikationsverlauf

Eingereicht: 11. Dezember 2022

Angenommen: 03. Mai 2023

Accepted Manuscript online:
08. Mai 2023

Artikel online veröffentlicht:
12. Juni 2023

• References

• 1 Aydin B, Caliskan A, Arga KY. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies. EPMA J 2021; 12 (03) 383-401
• 2 Peculis R, Rovite V, Megnis K. et al. Whole exome sequencing reveals novel risk genes of pituitary neuroendocrine tumors. PLoS One 2022; 17 (08) e0265306
• 3 Ntali G, Capatina C. Updating the landscape for functioning gonadotroph tumors. Medicina (Kaunas) 2022; 58 (08) 1071
• 4 Sato M, Tamura R, Tamura H. et al. Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med 2019; 8 (05) 695
• 5 Vergeer RA, Theunissen REP, van Elk T. et al. Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects. Rev Endocr Metab Disord 2022; 23 (03) 647-657
• 6 Ilie MD, Lasolle H, Raverot G. Emerging and novel treatments for pituitary tumors. J Clin Med 2019; 8 (08) 1107
• 7 Marques P, Barry S, Carlsen E. et al. The role of the tumour microenvironment in the angiogenesis of pituitary tumours. Endocrine 2020; 70 (03) 593-606
• 8 Marques P, Barry S, Carlsen E. et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun 2019; 7 (01) 172
• 9 Neou M, Villa C, Armignacco R. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 2020; 37 (01) 123-134.e5
• 10 Ghoshdastider U, Rohatgi N, Mojtabavi Naeini M. et al. Pan-cancer analysis of ligand-receptor cross-talk in the tumor microenvironment. Cancer Res 2021; 81 (07) 1802-1812
• 11 Ramilowski JA, Goldberg T, Harshbarger J. et al. A draft network of ligand-receptor-mediated multicellular signalling in human. Nat Commun 2015; 6: 7866
• 12 Chenlo M, Rodriguez-Gomez IA, Serramito R. et al. Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly. EBioMedicine 2019; 43: 537-552
• 13 Baloh RH, Tansey MG, Golden JP. et al. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron 1997; 18 (05) 793-802
• 14 Matsushita N, Kato Y, Katakami H, Shimatsu A, Yanaihara N, Imura H. Stimulation of growth hormone release by vasoactive intestinal polypeptide from human pituitary adenomas in vitro. J Clin Endocrinol Metab 1981; 53 (06) 1297-1300
• 15 Chihara K, Iwasaki J, Minamitani N. et al. Effect of vasoactive intestinal polypeptide on growth hormone secretion in perifused acromegalic pituitary adenoma tissues. J Clin Endocrinol Metab 1982; 54 (04) 773-779
• 16 Hsu DW, Riskind PN, Hedley-Whyte ET. Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study. Am J Pathol 1989; 135 (02) 329-338
• 17 Thiele JO, Lohrer P, Schaaf L. et al. Functional in vitro studies on the role and regulation of interleukin-6 in human somatotroph pituitary adenomas. Eur J Endocrinol 2003; 149 (05) 455-461
• 18 Han S, Yang CL, Chen X, Naes L, Cox BF, Westfall T. Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol 1998; 274 (01) H290-H294
• 19 Jansson JO, Svensson J, Bengtsson BA. et al. Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 1998; 48 (02) 243-250
• 20 Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 2009; 56 (04) 579-584
• 21 Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab 2013; 98 (02) 425-438
• 22 Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 2015; 18 (01) 108-115
• 23 Delgrange E, Maiter D, Donckier J, Tourniaire J. Influence of age on the clinical presentation of prolactinomas in male patients. Gerontology 1999; 45 (03) 160-164
• 24 Knerr I, Schuster S, Nomikos P. et al. Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans. Neuropathol Appl Neurobiol 2001; 27 (03) 215-222
• 25 Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 2019; 104 (07) 2473-2489
• 26 Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 2017; 176 (02) 195-201
• 27 Jin G, Kawsar HI, Hirsch SA. et al. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One 2010; 5 (06) e10993
• 28 Xu D, Zhang B, Liao C. et al. Human beta-defensin 3 contributes to the carcinogenesis of cervical cancer via activation of NF-κB signaling. Oncotarget 2016; 7 (46) 75902-75913
• 29 Huang CY, Chiang SF, Ke TW. et al. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Sci Rep 2018; 8 (01) 15658
• 30 Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989; 44: 265-311
• 31 Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors. Accessed September 20, 2020 at: https://ClinicalTrials.gov/show/NCT04042753